We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




New Microplate Reader Optimized for Fluorescent and Bioluminescent Assays

By LabMedica International staff writers
Posted on 13 Feb 2014
Print article
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Image: The GloMax Discover, an integrated multimode detection plate-reader system (Photo courtesy of the Promega Corporation).
Biotech and other life science researchers now have available a new microplate reader system that provides superior sensitivity, performance, and flexibility with minimal user intervention.

Promega Corporation (Madison, WI, USA) has launched the GloMax Discover, an integrated multimode detection plate-reader system. This system was designed to enable investigators to easily study cell signaling and metabolism, while monitoring cell viability, apoptosis, and cytotoxicity, or to study gene expression with a wide variety of reporter assays.

The instrument offers a broad dynamic range for both strong and weak bioluminescence experimental samples, superior luminescence sensitivity, and low well-to-well cross talk, which enables users to generate more usable data from each experiment. The GloMax Discover provides flexible use of filters for fluorescence intensity, BRET (bioluminescence resonance energy transfer), FRET (fluorescence resonance energy transfer), filtered luminescence, and UV-visible absorbance measurements. In addition, the system encourages seamless integration with industry-leading bioluminescent assays.

The GloMax Discover is driven by proprietary software that provides quick and easy navigation through the control options, preloaded assay protocols, and drag-and-drop protocol customization.

Michael Bjerke, global product manager, detection at Promega, said, “Scientific discoveries not only require the right type of assay to achieve the necessary sensitivity, dynamic range, and reproducibility, they require the right type of instrument. Instruments with enhanced optical capability, such as our GloMax systems with high quality luminescence, enable superior assay performance and experimental design.”

Related Links:

Promega Corporation


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Fully Automated Cell Density/Viability Analyzer
BioProfile FAST CDV

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A network of inflammatory molecules may act as biomarker for risk of future cerebrovascular disease (Photo courtesy of 123RF)

Simple Blood Test Could Enable First Quantitative Assessments for Future Cerebrovascular Disease

Cerebral small vessel disease is a common cause of stroke and cognitive decline, particularly in the elderly. Presently, assessing the risk for cerebral vascular diseases involves using a mix of diagnostic... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The ePlex system has been rebranded as the cobas eplex system (Photo courtesy of Roche)

Enhanced Rapid Syndromic Molecular Diagnostic Solution Detects Broad Range of Infectious Diseases

GenMark Diagnostics (Carlsbad, CA, USA), a member of the Roche Group (Basel, Switzerland), has rebranded its ePlex® system as the cobas eplex system. This rebranding under the globally renowned cobas name... Read more

Pathology

view channel
Image: The Aperio GT 450 DX has received US FDA 510(k) clearance (Photo courtesy of Leica Biosystems)

Use of DICOM Images for Pathology Diagnostics Marks Significant Step towards Standardization

Digital pathology is rapidly becoming a key aspect of modern healthcare, transforming the practice of pathology as laboratories worldwide adopt this advanced technology. Digital pathology systems allow... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.